November 24, 2016Thrombosis and Haemostasis
Cancer-associated venous thromboembolism: Burden, mechanisms, and management
Population
Cancer patients at risk for or with venous thromboembolism (VTE)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
LMWH remains standard for cancer-associated VTE; leaves open DOAC role pending head-to-head trials.
Structured PICO
P
Population
Cancer patients at risk for or with venous thromboembolism (VTE)
I
Intervention
Low-molecular-weight heparin (LMWH), direct oral anticoagulants (DOACs), and vitamin K antagonists
LMWH remains the standard of care for cancer-associated VTE, while DOACs are a promising option pending further head-to-head trials.
Cite This Study
Ay et al. (2016) studied this question.